Trial Profile
COMPASS 3: An Open-label, Multi-Center Study Employing a Targeted 6-MWT Distance Threshold Approach to Guide Bosentan-Based Therapy and to Assess the Utility of MRI on Cardiac Remodeling
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Mar 2014
Price :
$35
*
At a glance
- Drugs Bosentan (Primary) ; Sildenafil
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms COMPASS-3
- Sponsors Actelion Pharmaceuticals
- 25 Mar 2014 New trial record